Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

102,608 101,892 102,273 101,761

Effect of dilutive securities:

Conversion of CODES 14,357 - 14,357 -

Dilutive stock options 409 - 409 -

Diluted weighted average common

shares outstanding 117,374 101,892 117,039 101,761

Diluted earnings per share - Adjusted

Diluted earnings per share -

Adjusted $0.35 $0.25 $1.37 $1.02

Basic weighted average common

shares outstanding 102,608 101,892 102,273 101,761

Effect of dilutive securities:

Conversion of CODES 14,357 14,357 14,357 14,357

Dilutive stock options 409 222 409 234

Diluted weighted average common

shares outstanding 117,374 116,471 117,039 116,352

The following table presents a reconciliation of reported net income for the three and twelve months ended December 31, 2007 and 2006 to adjusted EBITDA:

Table 5

Watson Pharmaceuticals, Inc.

Adjusted EBITDA Reconciliation Table

(Unaudited; in millions)

Three Months Twelve Months

Ended December 31, Ended December 31,

2007 2006 2007 2006

GAAP net income (loss) $38.4 $(489.0) $141.0 $(445.0)

Plus:

Interest expense 9.0 11.6 44.5 22.1

Interest income (2.2) (5.6) (8.9) (28.4)

Provision for income

taxes 21.4 7.8 83.2 34.1

Depreciation 20.2 17.6 77.2 54.6

Amortization 44.2
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... 2013  Empire Genomics announced today it has ... novel genomic biomarker from Cornell University for use ... help in diagnosing and determining treatment for patients ... Neuroendocrine prostate cancer (NEPC) is a lethal variant ... novo, but more commonly arises after hormonal therapy ...
(Date:5/22/2013)... CANTON, Mass. and NEW ORLEANS ... commercial leader in the field of regenerative medicine, presented ... expert economists from Analysis Group (a leading health economics ... that diabetic foot ulcers (DFU) and venous leg ulcers ... The results of this research, which reveal annual ...
(Date:5/22/2013)... -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company ... Microcap Conference, May 30, in New York, NY ... , CPA, Chief Financial Officer of Cleveland BioLabs, will present ... 1:30 p.m. Eastern Time.  A live and archived webcast of ... of the Cleveland BioLabs website at www.cbiolabs.com . ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2
... 4, 2011 Tengion, Inc. (Nasdaq: TNGN ), ... a conference call and live audio webcast on Thursday, May ... update and discuss its first quarter 2011 financial results.   ... (domestic) or 1-617-597-5328 (international) and reference access code 64874944. ...
... Researchers at the Institute for Genome Sciences at the ... the FBI, the U.S. Army Medical Research Institute of ... first scientific paper based on their investigation into the ... its use of genomics and microbiology in a criminal ...
... to develop a new drug that will regenerate a ... a person is exposed to deadly chemical warfare agents. ... Ohio State University (OSU), is leveraging Ohio Supercomputer Center ... to lethal chemicals called organophosphorus (OP) nerve agents. ...
Cached Biology Technology:Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 3University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 4OSU chemist developing solution to nerve agent exposure 2
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
(Date:5/23/2013)... MADISON, Wis. In an age when microbial pathogens ... to tamp down infection, a team of Wisconsin scientists ... of curbing the bacteria that cause staph infections. , ... Chemical Society , a group led by University of ... interfere with the "quorum sensing" behavior of Staphylococcus ...
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2
... A combination of forest byproducts and crustacean shells may ... water, researchers from North Carolina State University have found. ... the major health risks posed by nuclear accidents is ... is chemically identical to non-radioactive iodide, the human body ...
... has been developed to carry out preimplantation genetic screening ... to the recipient uterus in the same in vitro ... The technique has been applied to the ... age, recurrent miscarriages or repeated implantation failures. ...
... NY) Just as inhaling cigarette smoke can cause lung ... Albert Einstein College of Medicine of Yeshiva University have ... of Health to clinically develop an inhaled therapy for lung ... and spreads. The grant recipients are Roman Perez-Soler, M.D., ...
Cached Biology News:Improvements in embryonic preimplantation genetic screening techniques 2NIH funds investigation of inhaled lung cancer treatment 2
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
p27 rabbit polyclonal antibody...
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Biology Products: